Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma.

Gordon RE, Zhang L, Peri S, Kuo YM, Du F, Egleston BL, Ng JMY, Andrews AJ, Astsaturov I, Curran T, Yang ZJ.

Clin Cancer Res. 2018 Mar 15;24(6):1375-1388. doi: 10.1158/1078-0432.CCR-17-2923. Epub 2018 Feb 6.

2.

Molecular characteristics of hepatocellular carcinomas from different age groups.

Ang C, Shields A, Xiu J, Gatalica Z, Reddy S, Salem ME, Farhangfar C, Hwang J, Astsaturov I, Marshall JL.

Oncotarget. 2017 Sep 27;8(60):101591-101598. doi: 10.18632/oncotarget.21353. eCollection 2017 Nov 24.

3.

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.

Lev A, Lulla AR, Wagner J, Ralff MD, Kiehl JB, Zhou Y, Benes CH, Prabhu VV, Oster W, Astsaturov I, Dicker DT, El-Deiry WS.

Oncotarget. 2017 Sep 12;8(47):81776-81793. doi: 10.18632/oncotarget.20819. eCollection 2017 Oct 10.

4.

Future Clinical Trials: Genetically Driven Trials.

Astsaturov I.

Surg Oncol Clin N Am. 2017 Oct;26(4):791-797. doi: 10.1016/j.soc.2017.05.014. Epub 2017 Aug 18. Review.

5.

Perspectives of HER2-targeting in gastric and esophageal cancer.

Gerson JN, Skariah S, Denlinger CS, Astsaturov I.

Expert Opin Investig Drugs. 2017 May;26(5):531-540. doi: 10.1080/13543784.2017.1315406. Review.

6.

LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma.

Naito S, Makhov P, Astsaturov I, Golovine K, Tulin A, Kutikov A, Uzzo RG, Kolenko VM.

Br J Cancer. 2017 Apr 25;116(9):1203-1207. doi: 10.1038/bjc.2017.77. Epub 2017 Mar 28.

7.

Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.

Bobrov E, Skobeleva N, Restifo D, Beglyarova N, Cai KQ, Handorf E, Campbell K, Proia DA, Khazak V, Golemis EA, Astsaturov I.

Oncotarget. 2017 Jan 17;8(3):4399-4409. doi: 10.18632/oncotarget.12642.

8.

EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer.

Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, Handorf EA, Dubyk C, Lango MN, Ridge JA, Astsaturov I, Serebriiskii IG, Burtness BA, Mehra R, Golemis EA.

Mol Cancer Ther. 2016 Oct;15(10):2486-2497. Epub 2016 Aug 9.

9.

Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study.

Vijayvergia N, Boland PM, Handorf E, Gustafson KS, Gong Y, Cooper HS, Sheriff F, Astsaturov I, Cohen SJ, Engstrom PF.

Br J Cancer. 2016 Aug 23;115(5):564-70. doi: 10.1038/bjc.2016.229. Epub 2016 Aug 2.

10.

The right and wrong of DOKing the nuclear receptor.

Astsaturov I.

EBioMedicine. 2016 Jun;8:7. doi: 10.1016/j.ebiom.2016.05.035. Epub 2016 May 28. No abstract available.

11.

Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.

Beglyarova N, Banina E, Zhou Y, Mukhamadeeva R, Andrianov G, Bobrov E, Lysenko E, Skobeleva N, Gabitova L, Restifo D, Pressman M, Serebriiskii IG, Hoffman JP, Paz K, Behrens D, Khazak V, Jablonski SA, Golemis EA, Weiner LM, Astsaturov I.

Clin Cancer Res. 2016 Dec 15;22(24):6153-6163. Epub 2016 Jul 6.

12.

Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.

Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA.

Am J Clin Oncol. 2017 Aug;40(4):393-398. doi: 10.1097/COC.0000000000000171.

13.

Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma.

Dotan E, Alpaugh RK, Ruth K, Negin BP, Denlinger CS, Hall MJ, Astsaturov I, McAleer C, Fittipaldi P, Thrash-Bingham C, Meropol NJ, Cohen SJ.

Pancreas. 2016 Sep;45(8):1131-5. doi: 10.1097/MPA.0000000000000619.

14.

Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR.

Gabitova L, Restifo D, Gorin A, Manocha K, Handorf E, Yang DH, Cai KQ, Klein-Szanto AJ, Cunningham D, Kratz LE, Herman GE, Golemis EA, Astsaturov I.

Cell Rep. 2015 Sep 22;12(11):1927-38. doi: 10.1016/j.celrep.2015.08.023. Epub 2015 Sep 3.

15.

HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.

Proia DA, Smith DL, Zhang J, Jimenez JP, Sang J, Ogawa LS, Sequeira M, Acquaviva J, He S, Zhang C, Khazak V, Astsaturov I, Inoue T, Tatsuta N, Osman S, Bates RC, Chimmanamada D, Ying W.

Mol Cancer Ther. 2015 Nov;14(11):2422-32. doi: 10.1158/1535-7163.MCT-15-0455. Epub 2015 Aug 13.

16.

Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer.

Shaikh T, Ruth K, Scott WJ, Burtness BA, Cohen SJ, Konski AA, Cooper HS, Astsaturov I, Meyer JE.

Ann Thorac Surg. 2015 Jan;99(1):270-6. doi: 10.1016/j.athoracsur.2014.08.033. Epub 2014 Nov 18.

17.

Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer.

Cohen SJ, Konski AA, Putnam S, Ball DS, Meyer JE, Yu JQ, Astsaturov I, Marlow C, Dickens A, Cade DN, Meropol NJ.

Br J Cancer. 2014 Jul 15;111(2):265-71. doi: 10.1038/bjc.2014.344. Epub 2014 Jul 1.

18.

Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.

Beeharry N, Banina E, Hittle J, Skobeleva N, Khazak V, Deacon S, Andrake M, Egleston BL, Peterson JR, Astsaturov I, Yen TJ.

Cell Cycle. 2014;13(14):2172-91. doi: 10.4161/cc.29214. Epub 2014 Jun 23.

19.

Successful imatinib therapy for neuroendocrine carcinoma with activating Kit mutation: a case study.

Perkins J, Boland P, Cohen SJ, Olszanski AJ, Zhou Y, Engstrom P, Astsaturov I.

J Natl Compr Canc Netw. 2014 Jun;12(6):847-52.

20.

Molecular pathways: sterols and receptor signaling in cancer.

Gabitova L, Gorin A, Astsaturov I.

Clin Cancer Res. 2014 Jan 1;20(1):28-34. doi: 10.1158/1078-0432.CCR-13-0122. Epub 2013 Oct 24. Review.

21.

Aurora kinases in head and neck cancer.

Mehra R, Serebriiskii IG, Burtness B, Astsaturov I, Golemis EA.

Lancet Oncol. 2013 Sep;14(10):e425-35. doi: 10.1016/S1470-2045(13)70128-1. Review.

22.

Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.

Liu H, Xiao F, Serebriiskii IG, O'Brien SW, Maglaty MA, Astsaturov I, Litwin S, Martin LP, Proia DA, Golemis EA, Connolly DC.

Clin Cancer Res. 2013 Sep 15;19(18):5053-67. doi: 10.1158/1078-0432.CCR-13-1115. Epub 2013 Jul 30.

23.

DUSP6 regulates drug sensitivity by modulating DNA damage response.

Bagnyukova TV, Restifo D, Beeharry N, Gabitova L, Li T, Serebriiskii IG, Golemis EA, Astsaturov I.

Br J Cancer. 2013 Aug 20;109(4):1063-71. doi: 10.1038/bjc.2013.353. Epub 2013 Jul 9.

24.

TRPV1 gates tissue access and sustains pathogenicity in autoimmune encephalitis.

Paltser G, Liu XJ, Yantha J, Winer S, Tsui H, Wu P, Maezawa Y, Cahill LS, Laliberté CL, Ramagopalan SV, DeLuca GC, Sadovnick AD, Astsaturov I, Ebers GC, Henkelman RM, Salter MW, Dosch HM.

Mol Med. 2013 Jul 24;19:149-59. doi: 10.2119/molmed.2012.00329.

25.

Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation.

Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, Egleston BL, Cunningham D, Bagnyukova T, Liu H, Nikonova A, Adams GP, Zhou Y, Yang DH, Mehra R, Burtness B, Cai KQ, Klein-Szanto A, Kratz LE, Kelley RI, Weiner LM, Herman GE, Golemis EA, Astsaturov I.

Cancer Discov. 2013 Jan;3(1):96-111. doi: 10.1158/2159-8290.CD-12-0031. Epub 2012 Nov 2.

26.

Aurora A kinase (AURKA) in normal and pathological cell division.

Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack RL Jr, Golemis EA.

Cell Mol Life Sci. 2013 Feb;70(4):661-87. doi: 10.1007/s00018-012-1073-7. Epub 2012 Aug 3. Review.

27.

Regulation of cholesterol biosynthesis and cancer signaling.

Gorin A, Gabitova L, Astsaturov I.

Curr Opin Pharmacol. 2012 Dec;12(6):710-6. doi: 10.1016/j.coph.2012.06.011. Epub 2012 Jul 21. Review.

28.

Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer.

Dotan E, Meropol NJ, Zhu F, Zambito F, Bove B, Cai KQ, Godwin AK, Golemis EA, Astsaturov I, Cohen SJ.

Br J Cancer. 2012 Feb 14;106(4):748-55. doi: 10.1038/bjc.2011.587. Epub 2012 Jan 12.

29.

Significance of pathologic response to preoperative therapy in pancreatic cancer.

Chun YS, Cooper HS, Cohen SJ, Konski A, Burtness B, Denlinger CS, Astsaturov I, Hall MJ, Hoffman JP.

Ann Surg Oncol. 2011 Dec;18(13):3601-7. doi: 10.1245/s10434-011-2086-4. Epub 2011 Sep 27.

PMID:
21947697
30.

Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment.

Wang S, Astsaturov IA, Bingham CA, McCarthy KM, von Mehren M, Xu W, Alpaugh RK, Tang Y, Littlefield BA, Hawkins LD, Ishizaka ST, Weiner LM.

Cancer Immunol Immunother. 2012 Jan;61(1):49-61. doi: 10.1007/s00262-011-1090-7. Epub 2011 Aug 13.

31.

Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?

Bagnyukova TV, Serebriiskii IG, Zhou Y, Hopper-Borge EA, Golemis EA, Astsaturov I.

Cancer Biol Ther. 2010 Nov 1;10(9):839-53. Epub 2010 Nov 1. Review.

32.

Synthetic lethal screen of an EGFR-centered network to improve targeted therapies.

Astsaturov I, Ratushny V, Sukhanova A, Einarson MB, Bagnyukova T, Zhou Y, Devarajan K, Silverman JS, Tikhmyanova N, Skobeleva N, Pecherskaya A, Nasto RE, Sharma C, Jablonski SA, Serebriiskii IG, Weiner LM, Golemis EA.

Sci Signal. 2010 Sep 21;3(140):ra67. doi: 10.1126/scisignal.2001083.

33.

Defining venous involvement in borderline resectable pancreatic cancer.

Chun YS, Milestone BN, Watson JC, Cohen SJ, Burtness B, Engstrom PF, Haluszka O, Tokar JL, Hall MJ, Denlinger CS, Astsaturov I, Hoffman JP.

Ann Surg Oncol. 2010 Nov;17(11):2832-8. doi: 10.1245/s10434-010-1284-9. Epub 2010 Aug 20.

PMID:
20725860
34.

Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.

Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu Z, Watson JC, Weiner LM, Cohen SJ.

Am J Clin Oncol. 2011 Feb;34(1):70-5. doi: 10.1097/COC.0b013e3181d2734a.

35.

Targeting EGFR resistance networks in head and neck cancer.

Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS.

Cell Signal. 2009 Aug;21(8):1255-68. doi: 10.1016/j.cellsig.2009.02.021. Epub 2009 Mar 1. Review.

36.

Mechanisms of tumor resistance to EGFR-targeted therapies.

Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I.

Expert Opin Ther Targets. 2009 Mar;13(3):339-62. doi: 10.1517/14712590902735795 . Review.

37.

Clinical application of EGFR inhibitors in head and neck squamous cell cancer.

Astsaturov I, Cohen RB, Harari PM.

Cancer Treat Res. 2008;139:135-52. Review. No abstract available.

PMID:
18236715
38.

The emerging role of cetuximab in head and neck cancer: a 2007 perspective.

Panikkar RP, Astsaturov I, Langer CJ.

Cancer Invest. 2008 Feb;26(1):96-103. doi: 10.1080/07357900701601002. Review.

PMID:
18181051
39.

EGFR-targeting monoclonal antibodies in head and neck cancer.

Astsaturov I, Cohen RB, Harari P.

Curr Cancer Drug Targets. 2007 Nov;7(7):650-65. Review.

PMID:
18045070
40.

Selective Raf inhibition in cancer therapy.

Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA.

Expert Opin Ther Targets. 2007 Dec;11(12):1587-609. Review. Erratum in: Expert Opin Ther Targets. 2009 Sep;13(9):1135.

41.

EGFR-targeting monoclonal antibodies in head and neck cancer.

Astsaturov I, Cohen RB, Harari PM.

Curr Cancer Drug Targets. 2006 Dec;6(8):691-710. Review.

PMID:
17168674
42.

Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer.

Astsaturov I, Cohen RB, Harari P.

Expert Rev Anticancer Ther. 2006 Sep;6(9):1179-93. Review.

PMID:
17020453
43.

Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100.

Spaner DE, Astsaturov I, Vogel T, Petrella T, Elias I, Burdett-Radoux S, Verma S, Iscoe N, Hamilton P, Berinstein NL.

Cancer. 2006 Feb 15;106(4):890-9.

44.

Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer.

Snyder LC, Astsaturov I, Weiner LM.

Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S71-80. Review.

PMID:
16336752
45.

Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines.

Astsaturov I, Petrella T, Bagriacik EU, de Benedette M, Uger R, Lumber G, Berinstein N, Elias I, Iscoe N, Hammond C, Hamilton P, Spaner DE.

Clin Cancer Res. 2003 Oct 1;9(12):4347-55.

46.

Primary Sjögren's syndrome and deficiency of ICA69.

Winer S, Astsaturov I, Cheung R, Tsui H, Song A, Gaedigk R, Winer D, Sampson A, McKerlie C, Bookman A, Dosch HM.

Lancet. 2002 Oct 5;360(9339):1063-9.

PMID:
12383988
47.

ICA69(null) nonobese diabetic mice develop diabetes, but resist disease acceleration by cyclophosphamide.

Winer S, Astsaturov I, Gaedigk R, Hammond-McKibben D, Pilon M, Song A, Kubiak V, Karges W, Arpaia E, McKerlie C, Zucker P, Singh B, Dosch HM.

J Immunol. 2002 Jan 1;168(1):475-82.

48.

T cells of multiple sclerosis patients target a common environmental peptide that causes encephalitis in mice.

Winer S, Astsaturov I, Cheung RK, Schrade K, Gunaratnam L, Wood DD, Moscarello MA, O'Connor P, McKerlie C, Becker DJ, Dosch HM.

J Immunol. 2001 Apr 1;166(7):4751-6.

49.

Type I diabetes and multiple sclerosis patients target islet plus central nervous system autoantigens; nonimmunized nonobese diabetic mice can develop autoimmune encephalitis.

Winer S, Astsaturov I, Cheung R, Gunaratnam L, Kubiak V, Cortez MA, Moscarello M, O'Connor PW, McKerlie C, Becker DJ, Dosch HM.

J Immunol. 2001 Feb 15;166(4):2831-41.

50.

Novel functional activities of anti-DNA autoantibodies from sera of patients with lymphoproliferative and autoimmune diseases.

Kozyr AV, Kolesnikov AV, Aleksandrova ES, Sashchenko LP, Gnuchev NV, Favorov PV, Kotelnikov MA, Iakhnina EI, Astsaturov IA, Prokaeva TB, Alekberova ZS, Suchkov SV, Gabibov AG.

Appl Biochem Biotechnol. 1998 Oct;75(1):45-61.

PMID:
10214696

Supplemental Content

Loading ...
Support Center